IBEX headed into its Q3 2026 print with a charged setup. Cost to borrow doubled in a week, short interest had been falling for a month, and options traders shifted abruptly toward calls. The result: a clean beat with raised guidance — and positioning that had already begun unwinding ahead of it.
The earnings story is the headline. Q3 adjusted EPS came in at $0.91 against a $0.85 estimate. Revenue hit $164.4 million, well above the $155.9 million consensus. Management followed the beat by raising full-year sales guidance to $638–642 million from $620–630 million, versus a prior street estimate of around $624.7 million. That's a meaningful top-end lift, and it arrives against a backdrop where short sellers had been cutting positions aggressively — short interest fell 24% over the past month to just 1.25% of free float.
The lending market told a more nuanced story heading in. Borrow availability had tightened materially even as shorts covered, with cost to borrow climbing from under 0.70% in late April to 1.35–1.49% in the days immediately before the print — more than doubling on the week. That compression in availability relative to a shrinking short base pointed to fewer shares changing hands in the lending pool, not new short-side conviction. The ORTEX short score held steady near 28.8, well below levels that would flag concentrated pressure.
Options positioning shifted sharply in the final sessions. The put/call ratio moved to 0.165, nearly three standard deviations above its 20-day mean of 0.139. At first glance that looks defensive, but the absolute level is still low — IBEX's 52-week PCR high is above 3.0. The move reflects relative repositioning into calls ahead of the catalyst, not broad hedging. Investors were leaning into the event, not against it.
The Street had been cautious but not hostile. The most recent analyst changes on record — both from late 2025 — show RBC Capital holding a Sector Perform with a $40 target and Baird downgrading to Neutral in May 2025 at $30. The mean target from the data is $37.50, against a current price of $28.35, implying room for re-rating if the raised guidance holds through the rest of the fiscal year. Note that the most recent changes are from November 2025, so any fresh analyst reaction to the Q3 print has yet to surface. The bull case centres on IBEX's 18%-plus revenue growth, the 82% digital/omnichannel mix, and early GenAI deployments moving from pilot to full scale. The bear case flags declines in telecoms and technology verticals and geopolitical exposure across delivery markets.
Institutional holders added a layer of interest this week. American Century Investment Management filed a Schedule 13G on May 1, disclosing a position of 619,000 shares — up 74,500 from its prior filing. The filing came just days before earnings, and American Century is now the third-largest institutional holder on record. CEO Robert Dechant sold 30,000 shares across five days in late February at prices between $28.46 and $29.98 — a steady, plan-style sale rather than a block. His 90-day net position, however, reflects a large award tranche in early February of 124,582 shares, leaving the insider ledger in net positive territory on shares over the window.
The prior two earnings prints provide context on post-event behaviour. The February 2026 report saw the stock fall 4.1% the next day and 12% over the following week. The print before that also declined over five days, dropping 13.5%. Both moves came despite the stock trading at similar price levels. Whether the guidance raise this time is enough to break that pattern — and whether the AI partnership with Sierra announced on May 5 adds incremental narrative — is what the next several sessions will reveal.
See the live data behind this article on ORTEX.
Open IBEX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
